title: Effects of coenzyme Q10 on arterial stiffness, metabolic parameters, and fatigue in obese subjects: a double-blind randomized controlled study.
abstract: This study investigated the effects of coenzyme Q(10) supplementation on metabolic parameters, inflammatory markers, arterial stiffness, and fatigue in obese subjects. We performed a randomized, double-blind, placebo-controlled, single-center study on 51 obese subjects with a body mass index (BMI) of ≥25 kg/m(2). Subjects were randomized into either a coenzyme Q(10) (200 mg/day) group (n = 26, BMI = 27.9 ± 2.3 kg/m(2), age = 42.7 ± 11.3 years) or a placebo group (n = 25, BMI = 26.8 ± 2.8 kg/m(2), age = 41.3 ± 11.2 years) for a 12-week study. We collected anthropometric measurements, blood for laboratory testing, brachial-ankle pulse wave velocity (baPWV) as an indicator of arterial stiffness, and responses to a fatigue severity scale (FSS) questionnaire at the initial (0 week) and final (12 weeks) visits. A total of 36 subjects successfully completed the study protocol. Serum coenzyme Q(10) levels increased significantly from 0.65 ± 0.27 μg/mL to 1.20 ± 0.38 μg/mL in the coenzyme Q(10) group (P < .001). Oral administration of coenzyme Q(10) did not significantly affect lipid profiles, oxidative and inflammatory markers [including lipoprotein (a), oxidized low-density lipoprotein level, C-reactive protein, and white blood cell count], or baPWV. The mean FSS score decreased significantly from 40.1 to 33.1 in the coenzyme Q(10) group (P = .017), but no significant change was seen in the placebo group (P = .464). However, the extents of the change in mean FSS score between the placebo and coenzyme Q(10) groups were not significantly different (P = .287). In conclusion, we found no evidence that coenzyme Q(10) affects fatigue index, arterial stiffness, metabolic parameters, or inflammatory markers.
authors.affiliation: Department of Family Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
authors.forename: Yong-Jae
authors.initials: YJ
authors.lastname: Lee
authors.forename: Wan-Je
authors.initials: WJ
authors.lastname: Cho
authors.forename: Jong-Koo
authors.initials: JK
authors.lastname: Kim
authors.forename: Duk-Chul
authors.initials: DC
authors.lastname: Lee
mesh_terms: D000284:Administration, Oral; D000328:Adult; D055109:Ankle Brachial Index; D001158:Arteries / Q000503:physiopathology*; D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000032:analysis; D008078:Cholesterol, LDL / Q000097:blood; D004311:Double-Blind Method; D005221:Fatigue / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000503:physiopathology*; D011795:Surveys and Questionnaires; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000494:pharmacology; D014655:Vascular Resistance / Q000187:drug effects*
chemical_list: D001786:Blood Glucose; D008078:Cholesterol, LDL; D014451:Ubiquinone; D002097:C-Reactive Protein; C024989:coenzyme Q10